# Bernard Gilly

> Bernard Gilly is a Series A investor at GenSight Biologics backing Computer and Health Care. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [GenSight Biologics](https://shizune.co/investors/profile/gensight-biologics)
- Location: Paris, France
- Total investments: 4
- Last investment: Nov 2020
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/bernard-gilly-17a8b795

Bernard Gilly is a Series A investor at GenSight Biologics in Paris focused on Computer and Health Care. Bernard Gilly is the Founder and CEO of GenSight Biologics. He previously worked at Fovea Pharmaceuticals, Sanofi as a CEO.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Computer | 1 | 25% |
| Health Care | 1 | 25% |
| Biotechnology | 1 | 25% |
| Semiconductor | 1 | 25% |
| Pharmaceutical | 1 | 25% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 25% |
| Series B | 1 | 25% |
| Series C | 1 | 25% |
| Funding Round | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 1 | 25% |
| United States | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| GrAI Matter Labs | GrAI Matter Labs (GML) is in the business of life-ready AI. Artificial Intelligence as close to natural as it gets. AI that feels alive. GrAI Matter Labs delivers brain-inspired chips that behave like humans do. That make machines assisting humans act, and react, in real time, live. Which optimizes energy and maximizes efficiency, saving time,money, and vital natural resources. Welcome to a AI-ready future, where robots, drones, autonomous vehicles, AR devices, surveillance cameras are smart, safe and convenient. Welcome to an optimized future. | $14M |  | Nov 23, 2020 |  |
| GrAI Matter Labs | GrAI Matter Labs (GML) is in the business of life-ready AI. Artificial Intelligence as close to natural as it gets. AI that feels alive. GrAI Matter Labs delivers brain-inspired chips that behave like humans do. That make machines assisting humans act, and react, in real time, live. Which optimizes energy and maximizes efficiency, saving time,money, and vital natural resources. Welcome to a AI-ready future, where robots, drones, autonomous vehicles, AR devices, surveillance cameras are smart, safe and convenient. Welcome to an optimized future. | $15M | Series A | Apr 12, 2018 |  |
| Sequoia Pharmaceuticals | Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics. | $35M | Series C | Jan 09, 2007 |  |
| Sequoia Pharmaceuticals | Sequoia Pharmaceuticals is a private, venture-capital funded company founded in 2002. They are engaged in the discovery and development of novel antiviral therapeutics with a focus on combating drug-resistant HIV and HCV. They are also developing pharmacokinetic enhancers to improve the exposure of co-administered therapeutics. | $22M | Series B | Mar 20, 2005 |  |

4 of 4 investments shown.

## Co-investors
- [360 Capital](https://shizune.co/investors/profile/360-capital-partners) — VC Fund, 2 deals together
- [3T Finance](https://shizune.co/investors/profile/3t-finance) — VC Fund, 2 deals together
- [Aberdare Ventures](https://shizune.co/investors/profile/aberdare-ventures) — VC Fund, 2 deals together
- [HealthCare Ventures](https://shizune.co/investors/profile/healthcare-ventures) — VC Fund, 2 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 1 deal together
- [Wellcome Trust](https://shizune.co/investors/profile/wellcome-trust) — VC Fund, 1 deal together

## About GenSight Biologics

VC Fund · Paris, France

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

5 contacts available at GenSight Biologics.

| Name | Title | Profile |
| --- | --- | --- |
| Bernard Gilly | Founder and CEO | https://shizune.co/investors/profile/bernard-gilly |
| Jean Bennett | Vice Chairman | https://shizune.co/investors/profile/jean-bennett |
| Jose Alain Sahel | Founder | https://shizune.co/investors/profile/jose-alain-sahel |
| Julio Benedicto | Vice President, Marketing | https://shizune.co/investors/profile/julio-benedicto |
| Luk Vandenberghe | Co-Founder | https://shizune.co/investors/profile/luk-vandenberghe |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Bernard Gilly invest in?

Bernard Gilly invests primarily in Computer, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bernard Gilly last invest?

The most recent investment recorded for Bernard Gilly closed in Nov 2020. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co